EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin

Jingli Lu iD, Yani Ma, Zhe Cao, Baoling Zhu, Luna Fan, Haiyang Meng iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01770-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Jingli Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Drug Combinations, Ceftazidime, Klebsiella pneumoniae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although polymyxins are a suboptimal option for difficult-to-treat resistant infections, they are still preferred as the first-line treatment, especially in low- and middle-income countries. This study assesses the efficacy of ceftazidime-avibactam (CAZ-AVI) following polymyxin B failure in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. We retrospectively reviewed cases of infections caused by CRKP in adults who received CAZ-AVI as salvage therapy. Clinical features and outcomes were described, and a logistic regression model was used to assess the risk factors associated with in-hospital crude mortality. One hundred and six patients were included in this study. The median age was 56 years. The most common infectious sites were lung. The patients received CAZ-AVI as salvage therapy for a median duration of 9 days following initial treatment with polymyxin B (median, 12.5 days). Also, 91 (85.8%) patients received CAZ-AVI combination therapy, and 34 (32.1%) patients received CAZ-AVI in combination with polymyxin B. The rate of in-hospital crude mortality was 25.5% (27/106), with the highest rate observed in patients treated with regimens containing polymyxin B (41.2%; 14/34). Therapeutic response was observed in 81 (76.4%) patients, with microbiological eradication achieved in 77.1% (74/96) of cases. Multivariable analysis identified that the length of intensive care unit stays, the sequential organ failure assessment (SOFA) score at CAZ-AVI withdrawal, and regimens containing polymyxin B were independently associated with in-hospital mortality, whereas the duration of CAZ-AVI treatment was independently associated with survival. CAZ-AVI salvage therapy demonstrated improved survival outcomes in patients who experienced failure with polymyxin B therapy. IMPORTANCE For patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) infections, published experience with salvage therapy is limited after the failure of polymyxin-based initial therapy. Here, we found that ceftazidime-avibactam salvage therapy for patients with CRKP infections offers benefit in mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsDrug CombinationsCeftazidimeKlebsiella pneumoniaeKlebsiella InfectionsAnti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaePolymyxin BHumansMiddle AgedFemaleMaleRetrospective StudiesAgedAdultCarbapenemsDrug Therapy, CombinationSalvage TherapyMicrobial Sensitivity TestsPolymyxinsTreatment Outcome

Stichwörter der Autor:innen

carbapenem-resistant Enterobacteriaceaeceftazidime-avibactampolymyxin Bsalvage therapy

Substanzen

avibactam, ceftazidime drug combinationAzabicyclo CompoundsDrug CombinationsCeftazidimeAnti-Bacterial AgentsPolymyxin BCarbapenemsPolymyxins

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
  • Department of Pharmacy, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Department of Pharmacy, Zhenping People's Hospital, Zhenping, China.
  • Department of Pharmacy, Xiangcheng Hospital of Chinese Medicine, Xiangcheng, China.
  • Department of Pharmacy, Huanghe Science and Technology College Affiliated Hospital, Zhengzhou, China.

ORCID-Profile: Jingli Lu, Haiyang Meng

Zitieren

APA

Lu, J., Ma, Y., Cao, Z., Zhu, B., Fan, L., & Meng, H. (2025). Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01770-24

Vancouver

Lu J, Ma Y, Cao Z, Zhu B, Fan L, Meng H. Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01770-24

BibTeX
@article{Lu2025,
  author = {Lu, Jingli and Ma, Yani and Cao, Zhe and Zhu, Baoling and Fan, Luna and Meng, Haiyang},
  title = {Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01770-24}
}
Kostenlos starten →